Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non-Small-Cell Lung Cancer.
Tan AC, Saw SPL, Chen J, Lai GGY, Oo HN, Takano A, Lau DPX, Yeong JPS, Tan GS, Lim KH, Skanderup AJ, Chan JWK, Teh YL, Rajasekaran T, Jain A, Tan WL, Ng QS, Kanesvaran R, Lim WT, Ang MK, Tan DSW. Tan AC, et al. Among authors: ng qs. JCO Precis Oncol. 2022 Oct;6:e2200278. doi: 10.1200/PO.22.00278. JCO Precis Oncol. 2022. PMID: 36240473
Truth about ERCC1 in lung cancer.
Tan DS, Ng QS, Tan IB, Lim ST, Lim WT. Tan DS, et al. Among authors: ng qs. J Clin Oncol. 2010 Apr 1;28(10):e162; author reply e164. doi: 10.1200/JCO.2009.26.6270. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159806 No abstract available.
Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers.
Tan EH, Goh C, Lim WT, Soo KC, Khoo ML, Tan T, Tan DS, Ang MK, Ng QS, Tan PH, Lim A, Hwang J, Teng YH, Lim TH, Tan SH, Baskaran N, Hui KM. Tan EH, et al. Among authors: ng qs. Ann Oncol. 2012 Apr;23(4):1010-6. doi: 10.1093/annonc/mdr327. Epub 2011 Jul 18. Ann Oncol. 2012. PMID: 21768327 Free article. Clinical Trial.
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, Soh S, Lee WH, Huang JW, Allen JC Jr, Woo XY, Nagarajan N, Kumar V, Thalamuthu A, Poh WT, Ang AL, Mya HT, How GF, Yang LY, Koh LP, Chowbay B, Chang CT, Nadarajan VS, Chng WJ, Than H, Lim LC, Goh YT, Zhang S, Poh D, Tan P, Seet JE, Ang MK, Chau NM, Ng QS, Tan DS, Soda M, Isobe K, Nöthen MM, Wong TY, Shahab A, Ruan X, Cacheux-Rataboul V, Sung WK, Tan EH, Yatabe Y, Mano H, Soo RA, Chin TM, Lim WT, Ruan Y, Ong ST. Ng KP, et al. Among authors: ng qs. Nat Med. 2012 Mar 18;18(4):521-8. doi: 10.1038/nm.2713. Nat Med. 2012. PMID: 22426421
82 results